







an Open Access Journal by MDPI

Pathology of Hematologic Malignancies

Guest Editor:

Dr. Aida I. Richardson

- Department of Pathology, Ann & Robert H. Lurie Children's
 Hospital of Chicago, Chicago, IL,
 USA
- 2. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Deadline for manuscript submissions:

31 October 2024

Message from the Guest Editor

Dear Colleagues,

Hematologic malignancies occur at all ages and can present as diseases of blood, lymph nodes, or solid organs. They can be indolent low-grade neoplasms or very aggressive, leading to death in a very short time. The classification of hematologic malignancies is based on clinical features, histology factors, immunophenotypes, as well as cytogenetic and molecular findings. Notably, in recent years, there is more knowledge on genetic changes in hematologic malignancies that has further impacted diagnostic criteria, as well as the development of the targeted treatment of these patients.

This Special Issue of *Cancers*, titled "Pathology of Hematologic Malignancy", aims to showcase original research articles or comprehensive review articles focused on significant clinicopathological, immunophenotypic, and genetic findings that can contribute to refining diagnostic, prognostic, or treatment criteria.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us